New hope for ALS patients: experimental drug trial seeks to slow devastating disease
NCT ID NCT07410806
Summary
This clinical trial is testing whether an experimental drug called NUZ-001 can slow the progression of ALS (amyotrophic lateral sclerosis) and help patients maintain physical function longer. The study involves 160 people with ALS who will receive either NUZ-001 or a placebo for comparison. Researchers will measure changes in patients' ability to perform daily activities, breathing function, and survival over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS ALS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Healey Center for ALS at Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.